Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: Histologically confirmed follicular non-Hodgkin's lymphoma (NHL) High-risk disease, as defined by any of the following: Relapsed within 6 months after the last treatment Failed to achieve a complete response during the last treatment Relapsed after prior autologous hematopoietic stem cell transplantation (HSCT) No current transformation of lymphoma (e.g., elements of intermediate- or high-grade lymphoma by biopsy) No active CNS disease by lumbar puncture or radiology scan NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age 16 to 70 Performance status Karnofsky 50-100% Life expectancy More than 16 weeks Hematopoietic Absolute neutrophil count > 500/mm^3 Hepatic Bilirubin ≤ 1.5 times upper limit of normal (ULN)* (unless due to Gilbert's disease) ALT ≤ 2.5 times ULN* NOTE: *Unless due to NHL Renal Creatinine ≤ 1.5 times ULN* OR Creatinine clearance ≥ 80 mL/min* NOTE: *Unless due to NHL Immunologic HIV negative Epstein-Barr virus positive No history of allergy or intolerance to ganciclovir Other Negative pregnancy test No history of another malignancy except basal cell skin cancer or carcinoma in situ No other uncontrolled or severe illness that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy No prior allogeneic HSCT No other immunotherapy during and for approximately 65 days after the last T-cell infusion, unless approved by the Principal Investigator (PI) Chemotherapy No other chemotherapy during and for approximately 65 days after the last T-cell infusion, unless approved by the PI Patients may receive chemotherapy after leukapheresis while waiting for CD19-specific T cells to be manufactured Endocrine therapy No systemic corticosteroids during and for approximately 65 days after the last T-cell infusion, unless approved by the PI Radiotherapy Not specified Surgery Not specified Other No concurrent participation in another investigational study No immunosuppression agents or other investigational agents during and for approximately 65 days after the last T-cell infusion, unless approved by the PI